TY - JOUR
T1 - Treatment of Bullous Pemphigoid With Dupilumab
T2 - A Case Series of 30 Patients
AU - Miller, Austinn C.
AU - Temiz, Laurie A.
AU - Adjei, Susuana
AU - Duran, Miguel A.
AU - Sassmannshausen, Jeffrey
AU - Dominguez, Arturo
AU - Thomas, Cristina
AU - Schmidt, Jimmy D.
AU - Bernhardt, Michael
AU - Doolittle-Amieva, Coley J.
AU - Moshiri, Ata S.
AU - Thompson, Anthony J.
AU - Kim-Lim, Penelope Pyoung
AU - Mattia, Alexzandra V.
AU - Tyring, Stephen K.
N1 - Publisher Copyright:
Copyright © 2024.
PY - 2024/6
Y1 - 2024/6
N2 - Bullous pemphigoid is often difficult to treat with the limited Penalties therapies Apply available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. We performed a multicenter, retrospective case series between March 2020 to August 2022. Patients received a loading dose of dupilumab 600 mg, followed by 300 mg maintenance dose with varying administration frequency tailored to individual patient response. All patients experienced at least some improvement in blister formation and pruritus, with 23 (76.7%) of patients demonstrating either complete clearance of blistering or marked response. Complete clearance of pruritus or marked response was noted in 25 (83.3%) of patients. Eight patients were effectively maintained solely on dupilumab. One (3.3%) patient reported an injection site reaction. Thirty patients represent a small sample, however, to our knowledge, this is the second largest group of BP treated with dupilumab. Furthermore, we provide an understandable framework for clinicians outside of academics to follow and assess treatment responses in their BP patients treated with dupilumab. Dupilumab should be considered as a therapeutic option in patients with bullous pemphigoid given its ability to induce sustained blistering and pruritus response in both typical and refractory cases while maintaining a favorable safety profile.
AB - Bullous pemphigoid is often difficult to treat with the limited Penalties therapies Apply available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. We performed a multicenter, retrospective case series between March 2020 to August 2022. Patients received a loading dose of dupilumab 600 mg, followed by 300 mg maintenance dose with varying administration frequency tailored to individual patient response. All patients experienced at least some improvement in blister formation and pruritus, with 23 (76.7%) of patients demonstrating either complete clearance of blistering or marked response. Complete clearance of pruritus or marked response was noted in 25 (83.3%) of patients. Eight patients were effectively maintained solely on dupilumab. One (3.3%) patient reported an injection site reaction. Thirty patients represent a small sample, however, to our knowledge, this is the second largest group of BP treated with dupilumab. Furthermore, we provide an understandable framework for clinicians outside of academics to follow and assess treatment responses in their BP patients treated with dupilumab. Dupilumab should be considered as a therapeutic option in patients with bullous pemphigoid given its ability to induce sustained blistering and pruritus response in both typical and refractory cases while maintaining a favorable safety profile.
UR - http://www.scopus.com/inward/record.url?scp=85195248926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195248926&partnerID=8YFLogxK
U2 - 10.36849/JDD.8258e
DO - 10.36849/JDD.8258e
M3 - Article
C2 - 38834228
AN - SCOPUS:85195248926
SN - 1545-9616
VL - 23
SP - e144-e148
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 6
ER -